FIGURE 11: IGP48 elicits variable IgG and IgM responses in human T. b. rhodesiense infections.

Recombinant IGP48 was resolved on a 10% SDS-PAGE gel. After Western Blotting, PVDF membranes were probed with plasma from T. b. rhodesiense patients and controls.

Lane M: molecular weight markers.

Lane 1 (from left): Ponceau red staining of IGP48 (*).

Lanes 2, 3 and 4: membrane probed with plasma L2 with anti-IgG, anti-IgM and no secondary antibody control respectively.

Lanes 5, 6 and 7: membrane probed with plasma L3 with anti-IgG, anti-IgM and no secondary antibody control respectively.

Lanes 8, 9 and 10: membrane probed with plasma L16 with anti-IgG, anti-IgM and no secondary antibody control respectively.

Lanes 11, 12 and 13: membrane probed with endemic control plasma LC7 with anti-IgG, anti-IgM and no secondary antibody control respectively.

Lanes 15 and 16: anti-IgG and IgM controls with no primary antibody.

For figures in higher resolution please refer to PDF version of the article.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.

Close